What is Chardan Capital’s Estimate for ANRO FY2025 Earnings?

by · The Cerbat Gem

Alto Neuroscience, Inc. (NYSE:ANRO – Free Report) – Chardan Capital issued their FY2025 earnings estimates for shares of Alto Neuroscience in a note issued to investors on Wednesday, November 19th. Chardan Capital analyst K. Nakae anticipates that the company will post earnings per share of ($2.45) for the year. Chardan Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. Chardan Capital also issued estimates for Alto Neuroscience’s FY2026 earnings at ($1.80) EPS.

Several other research firms also recently issued reports on ANRO. Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, October 8th. Jefferies Financial Group increased their price objective on Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. Robert W. Baird lifted their target price on Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Wall Street Zen raised Alto Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, BTIG Research assumed coverage on shares of Alto Neuroscience in a research note on Monday, November 17th. They set a “buy” rating and a $27.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $23.83.

Get Our Latest Stock Analysis on Alto Neuroscience

Alto Neuroscience Trading Up 0.1%

ANRO opened at $13.31 on Monday. The stock has a market capitalization of $413.57 million, a P/E ratio of -5.81 and a beta of 2.90. The company has a current ratio of 15.42, a quick ratio of 15.42 and a debt-to-equity ratio of 0.20. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $16.49. The firm’s fifty day simple moving average is $9.15 and its 200 day simple moving average is $5.12.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.14.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can acquired a new stake in shares of Alto Neuroscience in the 2nd quarter valued at approximately $25,000. Ground Swell Capital LLC bought a new stake in Alto Neuroscience during the second quarter worth $27,000. Vanguard Personalized Indexing Management LLC bought a new stake in Alto Neuroscience during the second quarter worth $33,000. AlphaCore Capital LLC lifted its stake in Alto Neuroscience by 100.0% in the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $44,000 after acquiring an additional 10,000 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in shares of Alto Neuroscience in the 1st quarter valued at about $52,000.

About Alto Neuroscience

(Get Free Report)

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

Featured Articles